Literature DB >> 9409752

Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way.

S Gamen1, A Anel, P Lasierra, M A Alava, M J Martinez-Lorenzo, A Piñeiro, J Naval.   

Abstract

It has recently been proposed that doxorubicin (DOX) can induce apoptosis in human T-leukemia cells via the Fas/FasL system in an autocrine/paracrine way. We show here that treatment of Jurkat cells with either anti-Fas antibodies, anthracyclin drugs or actinomycin D induces the activation of CPP32 (caspase-3) and apoptosis. However, DOX treatment did not induce the expression of membrane FasL or the release of soluble FasL and co-incubation with blocking anti-Fas antibodies prevented Fas-induced but not DOX-induced apoptosis. All the morphological and biochemical signs of apoptosis induced by anti-Fas or DOX can be prevented by Z-VAD-fmk, a general caspase inhibitor. DEVD-cho, a specific inhibitor of CPP32-like caspases which completely blocks Fas-mediated apoptosis, prevented drug-induced nuclear apoptosis but not cell death. We conclude that: (i) DOX-induced apoptosis in human T-leukemia/lymphoma is Fas-independent and (ii) caspase-3 is responsible of DOX-induced nuclear apoptosis but other Z-VAD-sensitive caspases are implicated in cell death.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9409752     DOI: 10.1016/s0014-5793(97)01282-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  21 in total

1.  Spontaneous apoptotic DNA fragmentation in cultured guinea pig gastric mucosal cells.

Authors:  S Tsutsumi; K Rokutan; T Tsuchiya; T Mizushima
Journal:  Dig Dis Sci       Date:  2000-02       Impact factor: 3.199

2.  Butyric acid-induced T-cell apoptosis is mediated by caspase-8 and -9 activation in a Fas-independent manner.

Authors:  T Kurita-Ochiai; K Ochiai; K Fukushima
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

3.  Ionizing radiation and chemotherapeutic drugs induce apoptosis in lymphocytes in the absence of Fas or FADD/MORT1 signaling. Implications for cancer therapy.

Authors:  K Newton; A Strasser
Journal:  J Exp Med       Date:  2000-01-03       Impact factor: 14.307

4.  Conserved molecular mechanisms underlying the effects of small molecule xenobiotic chemotherapeutics on cells.

Authors:  Hemant Sarin
Journal:  Mol Clin Oncol       Date:  2015-12-16

5.  Doxorubicin activates nuclear factor of activated T-lymphocytes and Fas ligand transcription: role of mitochondrial reactive oxygen species and calcium.

Authors:  Shasi V Kalivendi; Eugene A Konorev; Sonya Cunningham; Sravan K Vanamala; Eugene H Kaji; Joy Joseph; B Kalyanaraman
Journal:  Biochem J       Date:  2005-07-15       Impact factor: 3.857

6.  Induction of apoptosis in human mitogen-activated peripheral blood T-lymphocytes by the ether phospholipid ET-18-OCH3: involvement of the Fas receptor/ligand system.

Authors:  C Cabaner; C Gajate; A Macho; E Muñoz; M Modolell; F Mollinedo
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

7.  Inhibition of the PI3K/AKT Pathway Sensitizes Oral Squamous Cell Carcinoma Cells to Anthracycline-Based Chemotherapy In Vitro.

Authors:  Dmitriy Smolensky; Kusum Rathore; Jennifer Bourn; Maria Cekanova
Journal:  J Cell Biochem       Date:  2017-05-16       Impact factor: 4.429

8.  Chronic vascular toxicity of doxorubicin in an organ-cultured artery.

Authors:  T Murata; H Yamawaki; M Hori; K Sato; H Ozaki; H Karaki
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

9.  Interleukin-4 distinctively modifies responses of germinal centre-like and activated B-cell-like diffuse large B-cell lymphomas to immuno-chemotherapy.

Authors:  Kristopher A Sarosiek; Hovav Nechushtan; Xiaoqing Lu; Joseph D Rosenblatt; Izidore S Lossos
Journal:  Br J Haematol       Date:  2009-08-19       Impact factor: 6.998

10.  Inhibition of Girdin enhances chemosensitivity of colorectal cancer cells to oxaliplatin.

Authors:  Ya-Jie Zhang; A-Jian Li; Yi Han; Lu Yin; Mou-Bin Lin
Journal:  World J Gastroenterol       Date:  2014-07-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.